Wockhardt informs about press release

16 Dec 2024 Evaluate
Pursuant to Regulation 30 of Listing Regulations, Wockhardt has informed that it enclosed Press Release- ‘Zaynich™ (Zidebactam/Cefepime, WCK 5222) enables US cancer patient undergo successful liver transplant and resume chemotherapy by eradicating dual extreme-drug resistant Gram negative pathogens’. A copy of the same will also be uploaded on the Company’s website www.wockhardt.com.

The above information is a part of company’s filings submitted to BSE.









Wockhardt Share Price

1489.60 49.65 (3.45%)
24-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1817.60
Dr. Reddys Lab 1351.25
Cipla 1475.90
Lupin 2168.30
Zydus Lifesciences 964.40
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.